A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs MSC 2363318A (Primary) ; Tamoxifen; Trastuzumab
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors EMD Serono
- 28 Jun 2017 Planned number of patients changed from 130 to 129.
- 28 Jun 2017 Planned End Date changed from 30 Apr 2018 to 3 Jan 2019.
- 28 Jun 2017 Planned primary completion date changed from 30 Apr 2018 to 3 Jan 2019.